Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-A10 in advanced malignant tumors
NCT07205198Phase 1Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Oct 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIBP-A10 in cancer, sponsored by Shanghai Institute of Biological Products. Primary endpoints: Adverse Events and Phase II Recommended Dose. Started Oct 2025; status: recruiting.
02
Drugs
SIBP-A10
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07205198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205198.